References
- Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448–56
- Storr M, Meining A, Allescher HD. Pathophysiology and pharmacological treatment of gastroesophageal reflux disease. Dig Dis 2000;18:93–102
- Vakil N. Epigastric pain in dyspepsia and reflux disease. Rev Gastroenterol Disord 2003;3(Suppl 4):S16–21
- Spechler SJ. Epidemiology and natural history of gastrooesophageal reflux disease. Digestion 1992;51(Suppl 1):24–9
- Heading RC. Epidemiology of oesophageal reflux disease. Scand J Gastroenterol Suppl 1989;168:33–7
- Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965–73
- Revicki DA, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998;104:252–8
- Havelund T, Lind T, Wiklund I, et al. Quality of life in patients with heartburn but without esophagitis: Effects of treatment with omeprazole. Am J Gastroenterol 1999;94:1782–9
- Klinkenberg-Knol EC, Festen HP, Meuwissen SG. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995;49:695–710
- Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(Suppl 1):59–67
- Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9(Suppl):1: 3–7
- DiPalma JA. Management of severe gastroesophageal reflux disease. J Clin Gastroenterol 2001;32:19–26
- Denta J, Brunb J, Fendrickc AM, et al. on behalf of the Genval Workshop Group. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999;44(Suppl 2):S1–16
- Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. JCOM 2000;7:29–34
- Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adeno-carcinoma. N Engl J Med 1999;340:825–31
- Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis 2004;22:108–14